Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 8/20 | 0.36 |
| ▸ | CCR2 | P41597 | 4/20 | 0.33 |
| ▸ | UBE2M | P61081 | 3/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148370 | 0.96 | PSEN1 (0.36) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5148327 | 0.96 | SERPINE1 (0.36) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5150322 | 0.93 | TACR1 (0.40) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5148324 | 0.90 | CYP3A4 (0.37) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5147180 | 0.89 | SERPINE1 (0.37) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5148333 | 0.87 | SERPINE1 (0.35) | SERPINE1TACR1 | |
| SCHEMBL5148326 | 0.85 | TACR1 (0.39) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5149890 | 0.85 | TACR1 (0.39) | SERPINE1TACR1CCR2UBE2MDCUN1D1 | |
| SCHEMBL5147194 | 0.85 | TACR1 (0.36) | TACR1CCR2UBE2MDCUN1D1PSEN1 | |
| SCHEMBL5150976 | 0.84 | CYP3A4 (0.34) | TACR1UBE2MDCUN1D1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | SERPINE1 90/4885TACR1 1329/4885CCR2 2812/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | SERPINE1 423/4885TACR1 656/4885CCR2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.